BioPharma Marketing News | BioPharma Dive
The latest news in marketing in the biotech and biopharmaceutical industry.
Source: biopharmadive.com
📰 Johnson Rybrevant News
Page 2 - Johnson Rybrevant News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Johnson Rybrevant. Real-time updates on events, politics, business and more.
Tentarix Bio unveils $50M for biologics with multiple functions, multiple targets
Biotech startup Tentarix Biotherapeutics has come out of stealth with $50 million and technology that develops biologic drugs endowed with multiple functions. The company aims to develop new multispecific biologic drugs for cancer and autoimmune diseases.
Source: medcitynews.com
J&J's new cancer drug leads a growing pipeline of dual-targeting antibodies
*in combination with other drugs **enrollment paused SOURCE: Company disclosures, clinicaltrials.gov In multiple myeloma, many companies are taking aim at a disease-specific protein called BCMA, following the same approach of the approved drugs Blenrep from GlaxoSmithKline and Abecma from Bristol Myers Squibb. In leukemia and lymphoma, the target protein on the tumor cells is called CD20, to which the aging Roche drug Rituxan also binds. Roche is the most advanced using the CD20/CD3 approach, w...
Amgen Blincyto Bristol Myer Opdivo Bristol Myer Revlimid Johnson Rybrevant Bristol Myers Roche Hemlibra
Source: biopharmadive.com